Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia

被引：20
|
作者：
Sahin, Ilyas [1 ]
机构：
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 12期
关键词：
D O I：
10.1056/NEJMc1809507
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1186 / 1186
页数：1
相关论文
共 50 条
  • [21] Ivosidenib in acute myeloid leukemia
    Bruzzese, Antonella
    Labanca, Caterina
    Martino, Enrica Antonia
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Neri, Antonino
    Imovilli, Annalisa
    Morabito, Fortunato
    Vigna, Ernesto
    Gentile, Massimo
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (18) : 2093 - 2100
  • [22] Ivosidenib-azacitidine in acute myeloid leukemia with IDH1 R132 mutation
    Mechelfekh, Yaquine
    Gastaud, Lauris
    BULLETIN DU CANCER, 2023, 110 (12) : 1232 - 1233
  • [23] Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia
    Venugopal, Sangeetha
    Maiti, Abhishek
    DiNardo, Courtney D.
    Loghavi, Sanam
    Daver, Naval G.
    Kadia, Tapan M.
    Rausch, Caitlin R.
    Alvarado, Yesid
    Ohanian, Maro
    Sasaki, Koji
    Short, Nicholas J.
    Takahashi, Koichi
    Yilmaz, Musa
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (05) : E154 - E157
  • [24] Blockade of Glutathione Metabolism in IDH1-Mutated Glioma
    Tang, Xiaoying
    Fu, Xiao
    Liu, Yang
    Yu, Di
    Cai, Sabrina J.
    Yang, Chunzhang
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (01) : 221 - 230
  • [25] An IDH1-mutated primary gliosarcoma: case report
    Hsieh, Jason K.
    Hong, Christopher S.
    Manjila, Sunil
    Cohen, Mark L.
    Lo, Simon
    Rogers, Lisa
    Sloan, Andrew E.
    JOURNAL OF NEUROSURGERY, 2017, 126 (02) : 476 - 480
  • [26] Dermatologic adverse events in acute myeloid leukemia patients treated with IDH inhibitors ivosidenib and enasidenib
    Parisi, Rose
    Stoll, Joseph
    Zhu, Haoling
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB38 - AB38
  • [27] Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia
    Parisi, Rose
    Cowen, Emily A.
    Stoll, Joseph R.
    Zhu, Haoling
    Dusza, Stephen
    Pulitzer, Melissa P.
    Stein, Eytan M.
    Markova, Alina
    LEUKEMIA RESEARCH, 2022, 123
  • [28] Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia
    Lu, Jingtao
    Chen, Meiyu
    Hua, Haiying
    Qin, Wei
    Zhang, Ri
    Lu, Xuzhang
    Chao, Hongying
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (06) : 1483 - 1490
  • [29] Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia
    Gui, Gege
    Ravindra, Niveditha
    Hegde, Pranay S.
    Andrew, Georgia
    Mukherjee, Devdeep
    Wong, Zoe
    Auletta, Jeffery J.
    El Chaer, Firas
    Chen, Evan C.
    Chen, Yi-Bin
    Corner, Adam
    Devine, Steven M.
    Iyer, Sunil G.
    Jimenez Jimenez, Antonio Martin
    De Lima, Marcos J. G.
    Litzow, Mark R.
    Kebriaei, Partow
    Saber, Wael
    Spellman, Stephen R.
    Zeger, Scott L.
    Page, Kristin M.
    Dillon, Laura W.
    Hourigan, Christopher S.
    BONE MARROW TRANSPLANTATION, 2025, 60 (02) : 154 - 160
  • [30] Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study
    Sun, Mingyuan
    Yin, Qingsong
    Liang, Yang
    Chang, Chunkang
    Zheng, Jing
    Li, Jian
    Ji, Chunyan
    Qiu, Huiying
    Li, Junmin
    Gong, Yuping
    Luo, Sheng
    Zhang, Yan
    Chen, Rumei
    Shen, Zhenwei
    Yue, Zenglian
    Wang, Siyuan
    Shi, Qingmei
    Yang, Jason
    Jin, Jie
    Wang, Jianxiang
    BLOOD SCIENCE, 2024, 6 (03): : e00196
12345